Special articleConsensus on improving the comprehensive care of patients with acute heart failureConsenso para la mejora de la atención integral de los pacientes con insuficiencia cardíaca aguda☆
Introduction
The latest acute heart failure (AHF) consensus document from the Spanish Society of Cardiology (SEC, for its initials in Spanish), Spanish Society of Internal Medicine (SEMI, for its initials in Spanish), and Spanish Society of Emergency Medicine (SEMES, for its initials in Spanish) was published in 2015. Therefore, an update reviewing the various novelties regarding AHF that have emerged in recent years is necessary. These include the publication of new studies on the pharmacological treatment of patients with AHF during hospitalization and other recent developments such as early treatment, intermittent treatment, advanced heart failure, and refractory congestion. This consensus document was created with the aim of updating these aspects and creating a practical document that comprehensively describes the diagnosis, treatment, and management of this disease.
This document is an abridged version of the consensus document and describes the most essential parts of each section.
Section snippets
Methods
In order to create this document, a committee of coordinators who represent each of the three societies involved was formed and the following methodology was established:
- 1)
A bibliographic search for each section of the document principally using the MEDLINE and Embase databases and searching for relevant articles in the period from January 2015 to February 2019. The types of articles were, preferentially, randomized clinical trials, reviews, meta-analyses, consensus documents and guidelines, and
Funding
Novartis Farmacéutica S.A. provided financial support for this project. However, the development, interpretation of data, opinions, and drafting of this study have been carried out exclusively by the investigators.
Conflicts of interest
Dr. Juan F. Delgado receives fees for consulting or speaking from Novartis, AstraZeneca, Rovi, Medtronic, Abbott, Vifor, Amgen, Orion Pharma, and Impulse Dynamics.
Dr. Francesc Formiga has received fees for consulting, conferences, and attendance of congresses from Novartis and Rovi and consulting fees from Vifor and Pfizer.
Dr. Esteban López de Sá receives fees from Becton Dickinson, ZOLL Circulation, Boehringer Ingelheim, Daiichi Sankyo, and Ferrer.
Dr. Josep Masip receives fees for conferences
References (18)
- et al.
Péptidos natriuréticos: consenso y uso necesarios
Rev Esp Cardiol.
(2016) - et al.
Pathogenesis and clinical presentation of acute heart failure
Rev Esp Cardiol (Engl Ed).
(2015) - et al.
Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the assessment of frailty in elderly patients with heart disease
Rev Esp Cardiol (Engl Ed)
(2019) - et al.
Practical approach on frail older patients attended for acute heart failure
Int J Cardiol.
(2016) - et al.
Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization
JACC Heart Fail.
(2019) - et al.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
Eur Heart J.
(2016) - et al.
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry
Eur J Heart Fail.
(2017) - et al.
Consensus on improving the care integrated of patients with acute heart failure
Emergencias.
(2015) - et al.
Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail.
(2020)
Cited by (0)
- ☆
Please cite this article as: Delgado JF, Cepeda JM, Llorens P, Jacob J, Comín J, Montero M et al. Consenso para la mejora de la atención integral de los pacientes con insuficiencia cardíaca aguda. Rev Clin Esp. 2021;221:163–168.